NCT05978180已完成不适用
Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-articular Injection of 2.5 ml (SINOVIAL®ONE), in Symptomatic Gonarthrosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Labrha
- 入组人数
- 252
- 试验地点
- 50
- 主要终点
- To evaluate the efficacy of the two medical devices containing Pandora gel, HO-1 and HS-3, on walking pain in the target knee, compared to the SINOVIAL® ONE.
研究概览
简要总结
The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies.
The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly.
The present clinical investigation has the objective to evaluate the safety and efficacy of use of Pandora, a hyaluronic acid associated with tranexamic acid, in a single injection (HO-1) or in three injections performed weekly (HS-3), compared to a referred and commercialized medical device.
详细描述
This clinical investigation is a prospective, multicenter, randomized, parallel groups study of a class III Medical Device.
This study is designed to compare the safety of use and the efficacy of Pandora in its two forms : in a single injection (HO-1) or in three injections (HS-3) to a single intra-articular injection of 2.5 ml (SINOVIAL®ONE)
A descriptive analysis will be carried out to characterize the demographic data, the history of the disease and its treatments, the clinical and radiological data of the patients at inclusion.
The efficacy of Pandora will be demonstrated by describing the variation of WOMAC A1 score "walking pain" of target knee in repeated measures.
In total, 252 participants will be enrolled across 40 study centers in France and Monaco.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Single blind
入排标准
- 年龄范围
- 35 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged between 35 and 85 years.
- •Body mass index (BMI) < 35 kg.m
- •Medial or lateral femoro-tibial knee osteoarthritis, diagnosed according to the American College of Rheumatology criteria, radiological stage 2 and 3 according to the Kellgren-Lawrence criteria modified by Felson on an X-ray, of the knee in extension, less than 6 months old.
- •Knee osteoarthritis responsible for walking pain in the target knee, assessed between 4 and 8 inclusive on an 11 points numerical scale (0 = none to 10 = extreme).
- •Unilateral or bilateral knee osteoarthritis if the walking pain in the contralateral knee is < 3 based on 11 points numerical scale (0-10).
- •Ambulatory patient able to walk 50 meters without a cane, crutch or walker.
- •Patient giving his informed consent.
- •Patient agreeing to follow-up study visits.
- •Patient affiliated to the health social security system or beneficiary of such plan.
- •Patient requiring viscosupplementation according to the investigator.
排除标准
- •Patient presenting knee osteoarthritis without impingement joint space narrowing of the femoro-tibial compartment (modified Kellgren stage 0-1) or with complete impingement joint space narrowing on the knee weight-bearing radiograph in extension (modified Kellgren stage 4).
- •Patient with bilateral symptomatic gonarthrosis with walking pain of contralateral knee >
- •Patient with stage 4 patello-femoral osteoarthritis associated with femoro-tibial osteoarthritis.
- •Patient with a flare of osteoarthritis of the target or contralateral knee.
- •Patient who received viscosupplementation or Platelet Rich Plasma (PRP) injection, in the target knee, in the 6 months prior to inclusion.
- •Patient who received an intra-articular injection of corticosteroids in the target knee in the 2 months prior to inclusion.
- •Patients with a skin condition or a wound next to or near the injection site.
- •Patients refusing to discontinue treatment with NSAIDs or cox-2 inhibitors during the follow-up period.
- •Patient receiving treatment with level III analgesics (strong opioids).
- •Patients receiving treatment with diacerhein, avocado and soy unsaponifiables, glucosamine or chondroitin initiated less than 2 months prior to inclusion.
- •Patient with hypersensitivity to hyaluronic acid or tranexamic acid.
- •Patient with a history of seizures.
- •Patient who had arthroscopy of the target knee or major trauma to the target knee during the 3 months preceding inclusion.
- •Patient scheduled to undergo surgery, for any cause, of the target knee or other joint of the lower limbs, planned within 6 months of inclusion, likely to interfere with follow-up or evaluation of the patient in the study.
- •Patient with Fibromyalgia.
- •Patient with an active neurological or vascular musculoskeletal disorder (such as rheumatoid arthritis, lupus, psoriatic arthritis, spondyloarthritis or any other autoimmune disease, Paget's disease, gout, coxopathy, tendinopathy of the lower limb, sciatic or crural radiculalgia) which, in the opinion of the investigator, would be likely to disrupt regular monitoring and/or interfere with the measurement of evaluated knee treatment efficacy.
- •Patient with serious hemostasis disorders, venous or lymphatic stenosis of the lower limbs, history of thromboembolic disease - phlebitis or pulmonary embolism - or a high risk of thromboembolism.
- •Patients with renal insufficiency.
- •Patients with all evolving general condition as cardiac, digestive, endocrine, haematological or broncho-pulmonary which, in the opinion of the investigator, would be likely to disrupt regular monitoring and/or interfere with the measurement of evaluated knee treatment efficacy.
- •Breastfeeding patient, pregnant or wishing to be during the 12 months of the study.
- •Patients of childbearing age, sexually active without contraception.
- •Patients unable to give personal consent.
- •Patients participating or having participated in interventional research and whose follow-up ended within 2 months prior to inclusion.
结局指标
主要结局
To evaluate the efficacy of the two medical devices containing Pandora gel, HO-1 and HS-3, on walking pain in the target knee, compared to the SINOVIAL® ONE.
时间窗: 6 months
Variation of the WOMAC A1 score "walking pain" of the target knee in repeated measures (weeks 4,12 and 26), between the first or single injection and the potential injection at week 26.
次要结局
- To evaluate the efficacy of viscosupplementation by HO-1 and HS-3 on the pain of the target knee at weeks 4, 12 and 26 and week 12 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To evaluate, at S52, the benefit of the additional injection of HO-1 at S26 on analgesic drug consumption.(12 months)
- To evaluate the efficacy of viscosupplementation by HO-1 and HS-3 on walking pain of the target knee between day 1 and week 12.(3 months)
- To determine the number (and percentage) of patients requiring a new injection at S26.(6 months)
- To evaluate the efficacy of viscosupplementation by HO-1 and HS-3 on the function of target knee at weeks 4, 12, 26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To evaluate the efficacy of viscosupplémentation by HO-1 and HS-3 on the analgesic drug consumption at weeks 4, 12, 26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To determine the number (and percentage) of patients "OMERACT-OARSI responsive" at weeks 4,12,26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To determine the number (and percentage) of "highly responsive" patients at weeks 4, 12 and 26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To determine the number (and percentage) of patients in whom target knee pain is considered acceptable according to the PASS criterion at weeks 4,12 and 26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To determine the number (and percentage) of patients in whom the decrease of the target knee pain is considered important (MCII criterion) at weeks 4,12 and 26 as well as week 52 for patients who didn't require an injection at week 26.(12 months)
- To evaluate, at S52, the efficacy of the additional injection of HO-1 at S26 on pain and function of the target knee.(12 months)
- To evaluate the local tolerability (at the target knee), after each injection of HO-1 and HS-3, compared to SINOVIAL® ONE.(1 month)
- To assess patient's satisfaction regarding the tolerability of HO-1 treatment at week 27 for patients who received an injection at week 26.(6 months and one week (=27 weeks))
- To measure the self-reported treatment efficacy by the patient at weeks 4, 12, 26 and 52.(12 months)
- To assess patient's satisfaction regarding tolerability of HO-1 and HS-3 treatment between day 1 and week 4, compared to SINOVIAL® ONE.(1 month)
- To evaluate the global tolerability of HO-1 and HS-3 throughout the follow-up between day 1 and week 52 in comparison with SINOVIAL® ONE.(12 months)
研究者
研究点 (50)
Loading locations...
相似试验
已完成
不适用
Safety of Use of Pandora for Patients Suffering From GonarthrosisKnee OsteoarthritisNCT05414617Labrha20
已完成
2 期
Saline Injections vs Education and Exercise in Knee OsteoarthritisOsteoarthritis, KneeNCT03843931Marius Henriksen206
已完成
3 期
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee OsteoarthritisOsteoarthritisOsteoarthritis, KneeNCT02688400TRB Chemedica International SA380
撤回
不适用
Conventional Instrumentation, Computer Navigation, and Robotic Assistance Techniques in TKAKnee OsteoarthritisNCT05629715University of California, Los Angeles
已完成
不适用
Pulsed Radiofrequency to Relieve Knee PainPain SyndromeNCT03628482Gasthuis Zusters Antwerpen188